Friday, 20 Nov 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US

Kangerjia Medical

  • #
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
  • Rare / orphan disease drugs
  • Auto-immune
  • Vaccine
  • Cell-therapy
  • Multi-specific antibodies
  • CVD
  • AstraZeneca
  • Hengrui Pharmaceuticals
  • SHA: 600276
  • Diabetes
European Commission Approves Betta's Ensartinib as Gevalka – Next‑Generation ALK Inhibitor for Advanced NSCLC Marks Chinese Innovation's Entry Into the EU Market
CompanyDrug

European Commission Approves Betta’s Ensartinib as Gevalka – Next‑Generation ALK Inhibitor for Advanced NSCLC Marks Chinese Innovation’s Entry Into the EU Market

Betta Pharmaceuticals (SHE: 300558) announced that the Marketing Authorization Application (MAA) for ensartinib – submitted by Xcovery, its majority‑owned subsidiary – received approval from the European Commission. Indicated for the…

November 19, 2026
Huadong Medicine's HDM4002 Wins NMPA Clinical Trial Approval – First‑in‑Class CFB×MASP‑2 Bispecific Antibody Targets IgA Nephropathy With Dual Complement Blockade

Huadong Medicine’s HDM4002 Wins NMPA Clinical Trial Approval – First‑in‑Class CFB×MASP‑2 Bispecific Antibody Targets IgA Nephropathy With Dual Complement Blockade

November 19, 2026
Zelgen's ZG006 (Alveltamig) Hits Primary Endpoint in Pivotal Trial – First‑in‑Class DLL3xCD3 Trispecific T‑Cell Engager Advances Toward BLA for Third‑Line Small Cell Lung Cancer

Zelgen’s ZG006 (Alveltamig) Hits Primary Endpoint in Pivotal Trial – First‑in‑Class DLL3xCD3 Trispecific T‑Cell Engager Advances Toward BLA for Third‑Line Small Cell Lung Cancer

November 19, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Triastek Partners with Kangerjia to Develop 3D-Printed Modified Drugs for Sleep Disorders

October 28, 2024
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up